International Clinical Trial: Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529873) titled 'Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Condition: Squamous Cell Carcinoma of Head and Neck (SCCHN)

Intervention: Drug: Ficerafusp alfa

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 2026

Target Sample Size: 131

To know more, visit https://c...